Edgar Filing: PEDIATRIX MEDICAL GROUP INC

Form 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

x	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Quarterly Period Ended June 30, 2008

¨	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission File Number 001-12111

PEDIATRIX MEDICAL GROUP, INC.

(Exact name of registrant as specified in its charter)

Florida

65-0271219

(State or other jurisdiction of

incorporation or organization)

(I.R.S. Employer

Identification No.)

1301 Concord Terrace

Sunrise, Florida 33323

(Address of principal executive offices)

(Zip Code)

(954) 384-0175

(Registrant’s telephone number, including area code)

Not Applicable

(Former name, former address and fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.


Large accelerated filer x		Accelerated filer ¨		Non-accelerated filer ¨		Smaller reporting company ¨

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No x

Indicate the number of shares outstanding of each of the issuer’s classes of common stock as of the latest practicable date:

Shares of common stock outstanding as of July 31, 2008: 45,598,737.

PEDIATRIX MEDICAL GROUP, INC.

INDEX


		Page
PART I - FINANCIAL INFORMATION

ITEM 1.	Financial Statements	3

	Condensed Consolidated Balance Sheets as of June 30, 2008 and December 31, 2007 (Unaudited)	3

	Condensed Consolidated Statements of Income for the Three and Six Months Ended June 30, 2008 and 2007 (Unaudited)	4

	Condensed Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2008 and 2007 (Unaudited)	5

	Notes to Condensed Consolidated Financial Statements (Unaudited)	6

ITEM 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	15

ITEM 3.	Quantitative and Qualitative Disclosures About Market Risk	20

ITEM 4.	Controls and Procedures	20

PART II - OTHER INFORMATION

ITEM 1.	Legal Proceedings	21

ITEM 1A.	Risk Factors	22

ITEM 2.	Unregistered Sales of Equity Securities and Use of Proceeds	23

ITEM 4.	Submission of Matters to a Vote of Security-Holders	23

ITEM 6.	Exhibits	24

SIGNATURES		25

EXHIBIT INDEX		26

PART I - FINANCIAL INFORMATION

Item 1.

Financial Statements

PEDIATRIX MEDICAL GROUP, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited)


	June 30, 2008		December 31, 2007
	(in thousands)
ASSETS
Current assets:
Cash and cash equivalents	$	14,233	$	102,843
Short-term investments		22,989		18,042
Accounts receivable, net		148,605		145,504
Prepaid expenses		5,841		5,852
Deferred income taxes		44,358		53,390
Other assets		9,978		8,632
Assets held for sale		—		29,863

Total current assets		246,004		364,126
Investments		10,928		17,469
Property and equipment, net		35,046		31,162
Goodwill		904,675		858,919
Other assets, net		30,104		31,126

Total assets	$	1,226,757	$	1,302,802

LIABILITIES AND SHAREHOLDERS’ EQUITY
Current liabilities:
Accounts payable and accrued expenses	$	202,031	$	243,120
Current portion of long-term debt and capital lease obligations		204		469
Income taxes payable		19,144		19,192
Liabilities held for sale		—		2,106

Total current liabilities		221,379		264,887

Line of credit		57,500		—
Long-term debt and capital lease obligations		374		455
Deferred income taxes		42,935		40,489
Other liabilities		30,016		37,919

Total liabilities		352,204		343,750

Commitments and contingencies
Shareholders’ equity:
Preferred stock; $.01 par value; 1,000 shares authorized; none issued		—		—
Common stock; $.01 par value; 100,000 shares authorized; 45,560 and 48,421 shares issued and outstanding, respectively		456		484
Additional paid-in capital		541,120		556,836
Retained earnings		332,977		401,732

Total shareholders’ equity		874,553		959,052

Total liabilities and shareholders’ equity	$	1,226,757	$	1,302,802

The accompanying notes are an integral part of these Condensed Consolidated Financial Statements.

PEDIATRIX MEDICAL GROUP, INC.

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

(Unaudited)


	Three Months Ended June 30,						Six Months Ended June 30,
	2008			2007			2008			2007
	(in thousands, except per share data)
Net patient service revenue	$	257,704		$	223,262		$	503,277		$	434,186

Operating expenses:
Practice salaries and benefits		150,696			126,065			302,056			256,415
Practice supplies and other operating expenses		10,529			8,495			20,243			16,355
General and administrative expenses		31,016			29,300			60,772			62,331
Depreciation and amortization		2,939			2,219			5,755			4,397

Total operating expenses		195,180			166,079			388,826			339,498

Income from operations		62,524			57,183			114,451			94,688
Investment income		645			1,661			1,958			3,525
Interest expense		(335	)		(122	)		(720	)		(343	)

Income from continuing operations before income taxes		62,834			58,722			115,689			97,870
Income tax provision		24,662			23,019			45,388			37,174

Income from continuing operations		38,172			35,703			70,301			60,696

(Loss) income from discontinued operations, net of income taxes		(1,158	)		612			22,519			1,201

Net income	$	37,014		$	36,315		$	92,820		$	61,897

Per common and common equivalent share data:
Income from continuing operations:
Basic	$	0.82		$	0.74		$	1.49		$	1.25

Diluted	$	0.80		$	0.71		$	1.46		$	1.21

(Loss) income from discontinued operations:
Basic	$	(0.02	)	$	0.01		$	0.48		$	0.03

Diluted	$	(0.02	)	$	0.01		$	0.46		$	0.03

Net income:
Basic	$	0.80		$	0.75		$	1.97		$	1.28

Diluted	$	0.78		$	0.72		$	1.92		$	1.24

Weighted average shares:
Basic		46,481			48,537			47,027			48,453

Diluted		47,654			50,125			48,293			50,019

The accompanying notes are an integral part of these Condensed Consolidated Financial Statements.

PEDIATRIX MEDICAL GROUP, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)


	Six Months Ended June 30,
	2008			2007
	(in thousands)
Cash flows from operating activities:
Net income	$	92,820		$	61,897
Adjustments to reconcile net income to net cash provided from operating activities:
Depreciation and amortization		5,894			4,939
Stock-based compensation expense		9,889			8,322
Deferred income taxes		9,979			5,878
Gain on sale of assets		(36,237	)		—
Changes in assets and liabilities:
Accounts receivable		(3,139	)		(7,263	)
Prepaid expenses and other assets		(1,859	)		(3	)
Other assets		370			(310	)
Accounts payable and accrued expenses		(40,863	)		(27,326	)
Income taxes payable		118			(10,225	)
Other liabilities		(6,990	)		377

Net cash provided from operating activities		29,982			36,286

Cash flows from investing activities:
Acquisition payments, net of cash acquired		(47,654	)		(12,652	)
Purchase of investments		(8,690	)		(79,351	)
Proceeds from sales or maturities of investments		10,284			119,269
Purchase of property and equipment		(8,187	)		(3,345	)
Proceeds from sale of assets		66,000			—

Net cash provided from investing activities		11,753			23,921

Cash flows from financing activities:
Borrowings on line of credit		76,700			—
Payments on line of credit		(19,200	)		—
Payments on capital lease obligations		(362	)		(333	)
Excess tax benefit from exercises of stock options and vesting of restricted stock		3,951			1,887
Repurchases of common stock		(199,997	)		—
Proceeds from issuance of common stock		8,585			5,250

Net cash (used in) provided from financing activities		(130,323	)		6,804

Net (decrease) increase in cash and cash equivalents		(88,588	)		67,011
Cash and cash equivalents at beginning of period		102,843			69,595
Cash held by discontinued operating unit at beginning of period		50			—
Cash held by discontinued operating unit on sale date		(72	)		—

Cash and cash equivalents at end of period	$	14,233		$	136,606

The accompanying notes are an integral part of these Condensed Consolidated Financial Statements.

PEDIATRIX MEDICAL GROUP, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

June 30, 2008

(Unaudited)

1.	Basis of Presentation:

The accompanying unaudited Condensed Consolidated Financial Statements of Pediatrix Medical Group, Inc. and the notes thereto presented in this Form 10-Q have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (“SEC”) applicable to interim financial statements, and do not include all disclosures required by accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of management, these financial statements include all adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of the results of interim periods. The financial statements include all the accounts of Pediatrix Medical Group, Inc. and its consolidated subsidiaries (collectively, “PMG”) together with the accounts of PMG’s affiliated professional associations, corporations and partnerships (the “affiliated professional contractors”). PMG has contractual management arrangements with its affiliated professional contractors, which are separate legal entities that provide physician services in certain states and Puerto Rico. The terms “Pediatrix” and the “Company” refer collectively to Pediatrix Medical Group, Inc., its subsidiaries, and the affiliated professional contractors.

On February 29, 2008, the Company completed the sale of its newborn metabolic screening laboratory business in a cash transaction. In accordance with Statement of Financial Accounting Standards No. 144 (“FAS 144”), “Accounting for the Impairment or Disposal of Long-Lived Assets,” the assets and liabilities related to the laboratory business were classified as held for sale at December 31, 2007 and its operations are reported separately as income from discontinued operations, net of income taxes, for all periods presented. See Note 11 to the Condensed Consolidated Financial Statements for more information on the Company’s discontinued operations.

The consolidated results of operations for the interim periods presented are not necessarily indicative of the results to be experienced for the entire fiscal year. In addition, the accompanying unaudited Condensed Consolidated Financial Statements and the notes thereto should be read in conjunction with the Consolidated Financial Statements and the notes thereto included in the Company’s most recent Annual Report on Form 10-K.

2.	Summary of Significant Accounting Policies:

Stock Incentive Plans and Employee Stock Purchase Plans

In accordance with Statement of Financial Accounting Standards No. 123(R) (“FAS 123(R)”), the Company measures the cost of employee services received in exchange for stock-based awards based on grant-date fair value. As prescribed under FAS 123(R), the Company estimates the grant-date fair value of stock option grants using a valuation model known as the Black-Scholes-Merton formula or the “Black-Scholes Model” and allocates the resulting compensation expense over the corresponding requisite service period associated with each grant. The Black-Scholes Model requires the use of several variables to estimate the grant-date fair value of stock options, including expected term, expected volatility, expected dividends and risk-free interest rate. The Company performs significant analyses to calculate and select the appropriate variable assumptions used in the Black-Scholes Model. The Company also performs significant analyses to estimate forfeitures of stock-based awards as required by FAS 123(R). The Company is required to adjust its forfeiture estimates on at least an annual basis based on the number of share-based awards that ultimately vest. The selection of assumptions and estimated forfeiture rates is subject to significant judgment and future changes to these assumptions and estimates may have a material impact on the Condensed Consolidated Financial Statements. The Company recognizes compensation cost for stock-based compensation over the requisite service period using the graded vesting attribution method.

The Condensed Consolidated Statements of Income for the three and six months ended June 30, 2008 and 2007 include stock-based compensation expense calculated in accordance with FAS 123(R) for the Company’s stock incentive plans and the Company’s employee stock purchase plans. In addition, the Company’s Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2008 and 2007 include the excess tax benefits related to the exercise of stock options and the vesting of restricted stock as a cash inflow from financing activities. In accordance with Financial Accounting Standards Board (“FASB”) Staff Position No. FAS 123(R)-3, “Transition Election to Accounting for the Tax Effects of Share-Based Payment Awards,” the Company has elected to use the short-cut method to account for its historical pool of excess tax benefits related to stock-based awards. See Note 7 to the Condensed Consolidated Financial Statements for more information on the Company’s stock incentive plans and stock purchase plans.

Accounting Pronouncements

In December 2007, the FASB issued Statement of Financial Accounting Standards No. 141(R) (“FAS 141(R)”), “Business Combinations.” FAS 141(R) introduces significant changes in the accounting for and reporting of business acquisitions. FAS 141(R) continues the movement toward the greater use of fair values in financial reporting and increased transparency through expanded disclosures. FAS 141(R) changes how business acquisitions are accounted for and will impact financial statements at the acquisition date and in subsequent periods. Upon adoption, FAS 141(R) will require the Company to measure contingent consideration at fair value at the acquisition date, and will also require the Company to expense certain acquisition costs as they are incurred. In addition, FAS 141(R) will impact the annual goodwill impairment test associated with acquisitions. FAS 141(R) must be applied prospectively to business combinations for which the acquisition date is on or after the beginning of the first annual reporting period beginning on or after December 15, 2008. The Company has not yet completed its evaluation of the impact of FAS 141(R).

In September 2006, the FASB issued Statement of Financial Accounting Standards No. 157 (“FAS 157”), “Fair Value Measures.” FAS 157 creates a common definition for fair value for recognition or disclosure purposes under generally accepted accounting principles. FAS 157 also establishes a framework for measuring fair value and enhances disclosures about fair value measures required under other accounting pronouncements, but does not change existing guidance as to whether or not an instrument is carried at fair value. FAS 157 is effective for fiscal years beginning after November 15, 2007. As permitted by FASB Staff Position No. FAS 157-2, “Effective Date of FASB Statement No. 157,” the Company elected to defer the adoption of FAS 157 for all nonfinancial assets and nonfinancial liabilities, except those that are recognized or disclosed at fair value in the financial statements on a recurring basis. Although the partial adoption of FAS 157 on January 1, 2008 had no impact on the Company’s financial statements, the Company will continue to evaluate the impact of FAS 157 on its nonfinancial assets, including goodwill and intangible assets, upon final adoption in 2009. See Note 5 to the Condensed Consolidated Financial Statements for information on the Company’s cash equivalents and investments.

In April 2008, the FASB issued Staff Position (“FSP”) No. 142-3, “Determination of the Useful Lives of Intangible Assets.” This FSP amends the factors that should be considered in developing renewal or extension assumptions used to determine the useful life of a recognized intangible asset under Statement of Financial Accounting Standards No. 142 (“FAS 142”), “Goodwill and Other Intangible Assets.” The intent of the FSP is to improve the consistency between the useful life of a recognized intangible asset under FAS 142 and the period of expected cash flows used to measure the fair value of the asset. The guidance for determining the useful life of a recognized intangible asset shall be applied prospectively to intangible assets acquired after the effective date. This FSP shall be effective for consolidated financial statements issued for fiscal years beginning after December 15, 2008. The Company is currently evaluating the impact that FSP No. 142-3 will have on its consolidated financial statements.

Reclassifications

Reclassifications have been made to certain prior period financial statements to conform with the current quarter presentation.

3.	Accounts Receivable:

Accounts receivable consist of the following (in thousands):


	June 30, 2008			December 31, 2007
Gross accounts receivable	$	484,647		$	458,635
Allowance for contractual adjustments and uncollectibles		(336,042	)		(313,131	)

	$	148,605		$	145,504

4.	Business Acquisitions:

The Company acquired five physician group practices and made contingent purchase price payments on certain prior period acquisitions during the six months ended June 30, 2008. In connection with these acquisition payments, the Company recorded goodwill of approximately $45.8 million and other identifiable intangible assets consisting of physician and hospital agreements of approximately $1.9 million. The Company has not yet completed the purchase price allocation for certain of the physician group practices acquired during the six months ended June 30, 2008, but management does not believe the additional adjustments are material.

Certain purchase agreements related to the Company’s acquisitions contain contingent purchase price provisions based on volume and other performance measures. Potential payments under these provisions are not contingent upon the future employment of the sellers. The amount of the payments due under these provisions cannot be determined until the specific targets or measures are attained. In some cases, the sellers are eligible for annual contingent purchase price payments over a two-to-five year period based on the growth in profitability of the physician practice with no stated limit on the annual payment amount. Under all other contingent purchase price provisions, payments of up to $24.2 million may be due through 2012 as of June 30, 2008.

The results of operations of each of the practices acquired during the six months ended June 30, 2008 have been included in the Company’s Condensed Consolidated Financial Statements from its date of acquisition. The following unaudited pro forma information combines the consolidated results of operations of the Company and the physician group practice operations acquired during 2008 and 2007 as if the transactions had occurred at the beginning of the respective periods (in thousands, except for per share data):


	Three Months Ended June 30,				Six Months Ended June 30,
	2008		2007		2008		2007
Net patient service revenue	$	260,948	$	249,784	$	514,612	$	488,188
Net income	$	37,485	$	39,641	$	94,427	$	68,766
Net income per share:
Basic	$	0.81	$	0.82	$	2.01	$	1.42
Diluted	$	0.79	$	0.79	$	1.96	$	1.37

The pro-forma results do not necessarily represent results which would have occurred if the acquisitions had taken place at the beginning of the period, nor are they indicative of the results of future combined operations.

5.	Cash Equivalents and Investments:

Effective January 1, 2008, certain cash equivalents carried by the Company are subject to the provisions of FAS 157. Under FAS 157, the Company is required to measure the fair value of its financial assets using a three-tier fair value hierarchy. Based on this hierarchy, the Company determined the fair value of its money market funds using quoted market prices, a Level 1 or an observable input as defined under FAS 157. As of June 30, 2008, the Company’s cash equivalents consisted entirely of money market funds with a fair value of approximately $9.5 million.

Investments consist of held-to-maturity securities issued primarily by the U.S. Treasury, other U.S. Government corporations and agencies and states of the United States. Investments with remaining maturities of less than one year are classified as short-term investments. Investments classified as long-term have maturities of one to three years.

The Company intends and has the ability to hold its held-to-maturity securities to maturity, and therefore carries such investments at amortized cost in accordance with the provisions of Financial Accounting Standards No. 115, “Accounting for Certain Investments in Debt and Equity Securities.” Held-to-maturity securities are not subject to the fair value requirements of FAS 157.

The Company’s investments held at June 30, 2008 and December 31, 2007 are summarized as follows (in thousands):


	June 30, 2008				December 31, 2007
	Short-Term		Long-Term		Short-Term		Long-Term
U.S. Treasury Securities	$	508	$	—	$	500	$	—
Federal Home Loan Securities		5,571		3,255		4,901		2,614
Municipal Debt Securities		16,410		7,673		12,641		13,355
Federal Farm Credit Bank Discount Note		500		—		—		1,500

	$	22,989	$	10,928	$	18,042	$	17,469

6.	Accounts Payable and Accrued Expenses:

Accounts payable and accrued expenses consist of the following (in thousands):


	June 30, 2008		December 31, 2007
Accounts payable	$	10,397	$	5,574
Accrued salaries and bonuses		65,543		119,687
Accrued payroll taxes and benefits		15,966		14,984
Accrued professional liability risks		83,390		75,091
Accrual for uncertain tax positions (Note 8)		14,356		12,922
Other accrued expenses		12,379		14,862

	$	202,031	$	243,120

The net decrease in accrued salaries and bonuses from $119.7 million at December 31, 2007 to $65.5 million at June 30, 2008 is primarily due to the decrease in the Company’s liabilities for performance-based incentive compensation during the first quarter of 2008, partially offset by performance-based incentive compensation accrued during the six months ended June 30, 2008. A majority of the Company’s payments for performance-based incentive compensation is paid annually in the first quarter of each year.

7.	Stock Incentive Plans and Stock Purchase Plans:

On May 23, 2008, the Company’s shareholders approved the 2008 Incentive Compensation Plan (the “2008 Incentive Plan”). The terms of the 2008 Incentive Plan provide for grants of stock options, stock appreciation rights, restricted stock, deferred stock, and other stock-related awards and performance awards that may be settled in cash, stock or other property. As provided in the 2008 Incentive Plan, no additional grants can be made from the Company’s prior incentive plans, except that new awards will be permitted under the 2004 Incentive Compensation Plan (the “2004 Incentive Plan”) to the extent that shares previously granted under the 2004 Incentive Plan are forfeited, expire or terminate. Under the 2008 Incentive Plan, a total of 6 million shares are available for the granting of awards, inclusive of the number of shares remaining available for grant under the 2004 Incentive Plan. To date, the only equity awards made by the Company under the 2008 Incentive Plan are for stock options and restricted stock. Collectively, the Company’s prior incentive plans and the 2008 Incentive Plan are the Company’s Stock Incentive Plans (the “Stock Incentive Plans”). The Company also has employee Stock Purchase Plans (the “Stock Purchase Plans”) under which employees may purchase the Company’s common stock at 85% of market value on designated dates.

Under the 2008 Incentive Plan, options to purchase shares of common stock may be granted at a price not less than fair market value of the shares on the date of grant. The options must be exercised within 10 years from the date of grant and generally become exercisable on a pro rata basis over a three-year period from the date of grant. Restricted stock awards generally vest over periods of three years upon the fulfillment of specified service-based conditions and in certain instances performance-based conditions. The Company recognizes compensation expense related to its restricted stock awards ratably over the corresponding vesting periods. During the six months ended June 30, 2008, the Company granted approximately 742,000 stock options and approximately 225,000 shares of restricted stock to its employees under the Stock Incentive Plans. At June 30, 2008, the Company had approximately 4.8 million shares available for future grants and awards under the 2008 Incentive Plan. During the six months ended June 30, 2008, approximately 59,000 shares were issued under the Stock Purchase Plans. At June 30, 2008, the Company had approximately 49,000 shares reserved under the Stock Purchase Plans.

During the three and six months ended June 30, 2008 and 2007, the Company recognized approximately $4.9 million and $9.9 million, and $3.8 million and $8.3 million, respectively, of stock-based compensation expense related to the Stock Incentive Plans and the Stock Purchase Plans. The excess tax benefit recognized in additional paid-in capital related to the exercise of stock options and the vesting of restricted stock for the six months ended June 30, 2008 was approximately $4.1 million.

8.	Accounting for Uncertain Tax Positions:

As of June 30, 2008 and December 31, 2007, the Company’s total liability for unrecognized tax benefits was $22.0 million and $29.8 million, respectively. The Company had approximately $20.0 million of unrecognized tax benefits that, if recognized, would favorably impact its effective tax rate at June 30, 2008.

The Company includes interest and penalties related to income tax liabilities in income tax expense. As of June 30, 2008 and December 31, 2007, the Company’s accrued interest and penalties totaled $9.0 million and $6.7 million, respectively. Interest and penalties included in income tax expense for the six months ended June 30, 2008 totaled $2.3 million.

The Company’s liability for uncertain tax positions could be reduced over the next 12 months by approximately $6.4 million, excluding accrued interest, due to the expiration of statutes of limitation or settlements with taxing authorities. Additionally, the Company anticipates that its liability for uncertain tax positions will be increased over the next 12 months by additional taxes of approximately $2.2 million. Although the Company anticipates additional changes in its liability for uncertain tax positions related to certain temporary differences, an estimate of the range of such changes cannot be made at this time.

The Company is subject to taxes in the United States, the states in which it operates, and the Commonwealth of Puerto Rico. Significant judgment is required in evaluating the Company’s tax positions and determining its provision for taxes. The Company’s tax returns are routinely audited in the ordinary course of business and settlements of issues raised in these audits can sometimes affect the Company’s tax provisions. The Company is currently subject to U.S. Federal income tax examinations for the tax years 2004 through 2007 and Commonwealth of Puerto Rico income tax examinations for the tax years 2001 and 2003 through 2007.

The following table summarizes the activity related to the Company’s unrecognized tax benefits for the six months ended June 30, 2008 (in thousands):


Balance at December 31, 2007	$	29,769
Increases related to prior year tax positions		4,547
Decreases related to prior year tax positions		(8,919	)
Increases related to current year tax positions		1,236
Decreases related to current year tax positions		(1,710	)
Settlements		(2,905	)

Balance at June 30, 2008	$	22,018

At June 30, 2008, accounts payable and accrued expenses and other liabilities as presented in the Company’s Condensed Consolidated Balance Sheets include $10.5 million and $11.5 million, respectively, related to the Company’s total liability for unrecognized tax benefits of $22.0 million. At December 31, 2007, accounts payable and accrued expenses and other liabilities as presented in the Company’s Condensed Consolidated Balance Sheets include $11.6 million and $18.2 million, respectively, related to the Company’s total liability for unrecognized tax benefits of $29.8 million.

9.	Common and Common Equivalent Shares:

Basic net income per share is calculated by dividing net income by the weighted average number of common shares outstanding during the period. Diluted net income per share is calculated by dividing net income by the weighted average number of common and potential common shares outstanding during the applicable period. Potential common shares consist of the dilutive effect of outstanding options and non-vested restricted stock calculated using the treasury- stock method. Under the treasury-stock method, the Company calculates the assumed excess tax benefits related to the potential exercise or vesting of its stock-based awards using the difference between the average market price for the applicable period less the option price, if any, and the fair value of the stock-based award on the date of grant multiplied by the applicable tax rate.

The calculation of shares used in the basic and diluted net income per share calculation for the six months ended June 30, 2008 and 2007 is as follows (in thousands):


	Three Months Ended June 30,		Six Months Ended June 30,
	2008	2007	2008	2007
Weighted average number of common shares outstanding	46,481	48,537	47,027	48,453
Weighted average number of dilutive common shares equivalents	1,173	1,588	1,266	1,566

Weighted average number of common and common equivalent shares outstanding	47,654	50,125	48,293	50,019

For the three months ended June 30, 2008 and 2007, the Company had approximately 51,000 and 393,000 anti-dilutive outstanding employee stock options, respectively, that have been excluded from the computation of diluted earnings per share. For the six months ended June 30, 2008 and 2007, the Company had approximately 50,000 and 393,000 anti-dilutive outstanding employee stock options, respectively, that have been excluded from the computation of diluted earnings per share. For the three and six months ended June 30, 2008, the Company had approximately 224,000 shares of anti-dilutive unvested restricted stock that have been excluded from the computation of earnings per share.

10.

Common Stock Repurchase Program:

In December 2007, the Company’s Board of Directors authorized a $100 million share repurchase program subject to price, general economic and market conditions and trading restrictions. The Company completed this repurchase program in March 2008 by repurchasing approximately 1.5 million shares of its common stock for approximately $100 million.

In May 2008, the Company’s Board of Directors authorized an additional $100 million share repurchase program subject to price, general economic and market conditions and trading restrictions. In June 2008, the Company completed this repurchase program by repurchasing approximately 1.9 million shares of its common stock for approximately $100 million.

11.

Discontinued Operations:

On February 29, 2008, the Company completed the sale of its newborn metabolic screening laboratory business in a cash transaction for gross proceeds of approximately $66.0 million. The acquiring entity may make certain tax elections that will result in additional proceeds to the Company. Any such additional proceeds will be directly offset by an increase in the Company’s tax provision. The Company has retained contingent liabilities relating to certain unresolved legal matters as of the sale date. The Company believes that the outcome of these legal matters will not have a material adverse effect on its business, financial condition or results of operations.

During the three months ended June 30, 2008, the Company corrected certain deferred taxes related to its newborn metabolic screening laboratory business attributable to basis differences between financial reporting and tax reporting. As a result, the Company’s pretax and after-tax gain on the sale was reduced from $38.1 million to $36.2 million, and from $23.2 million to $22.0 million, respectively.

In accordance with FAS 144, the assets and liabilities related to the laboratory business were classified as held for sale at December 31, 2007, and its business operations are considered discontinued operations for all periods presented.

The following assets and liabilities were classified as current assets and liabilities held for sale at December 31, 2007 (in thousands):


Assets Held for Sale:
Cash and cash equivalents	$	50
Accounts receivable, net		1,862
Prepaid expenses		135
Deferred income taxes		482
Other current assets		675
Property and equipment, net		640
Goodwill		24,772
Other assets, net		1,247

Assets held for sale	$	29,863

Liabilities Held for Sale:
Accounts payable and accrued expenses	$	162
Deferred income taxes		1,944

Liabilities held for sale	$	2,106

Income from discontinued operations, net of income taxes, as reported in the Company’s Condensed Consolidated Statements of Income for the six months ended June 30, 2008, includes net patient service revenue of $2.5 million. Income from discontinued operations, net of income taxes, as reported in the Company’s Condensed Consolidated Statements of Income for the three and six months ended June 30, 2007, includes net patient service revenue of $3.5 million and $7.1 million, respectively. Pretax loss included in income from discontinued operations for the three months ended June 30, 2008 of $1.9 million is related to the revision of the gain calculation as described above. Pretax profit, excluding the pretax gain on sale, included in income from discontinued operations for the six months ended June 30, 2008 was $864,000. Pretax profit included in income from discontinued operations for the three and six months ended June 30, 2007 was $1.1 million and $2.1 million, respectively. The pretax gain on sale included in income from discontinued operations for the six months ended June 30, 2008 was $36.2 million.

12.

Commitments and Contingencies:

In July 2007, the Audit Committee of the Board of Directors concluded a comprehensive review of the Company’s historical practices related to the granting of stock options with the assistance of independent legal counsel and forensic accounting experts. At the commencement of the review, the Company voluntarily contacted the staff of the Securities and Exchange Commission (“SEC”) regarding the Audit Committee’s review and subsequently the SEC notified the Company that it had commenced a formal investigation into the Company’s stock option granting practices. The Company also had discussions with the U.S. Attorney’s office for the Southern District of Florida regarding the Audit Committee’s review and, in response to a subpoena, provided the office with various documents and information related to its stock option granting practices. The Company intends to continue full cooperation with the U.S. Attorney’s office and the SEC. The Company cannot predict the outcome of these matters.

In April 2008, the United States District Court for the Southern District of Florida entered a final judgment approving a Stipulation of Settlement to resolve a shareholder derivative lawsuit that was filed by Jacob Schwartz in the United States District Court for the Southern District of Florida in August 2007, naming the Company as a nominal defendant and also naming as defendants certain of the Company’s current and former officers and directors. The lawsuit alleged that all or some of the defendant officers and directors, among other things, breached their fiduciary duties to the Company, violated the federal securities laws, and engaged in corporate waste, gross mismanagement, unjust enrichment and constructive fraud in connection with the Company’s historical stock option practices. In consideration for the full settlement and release of claims against all defendants, the Stipulation of Settlement provided for the Company’s payment of $1.5 million in attorneys’ fees and costs to the plaintiff’s counsel and recognition that the plaintiff’s demand letter, which was received prior to the commencement of the lawsuit, was a significant contributing factor to the implementation of various measures to enhance the Company’s stock option practices. The payment to the plaintiff’s counsel was covered by insurance.

In September 2006, the Company completed a final settlement agreement with the Department of Justice and a relator who initiated a “qui tam” complaint against the Company relating to its billing practices for services reimbursed by Medicaid, the Federal Employees Health Benefit program, and the United States Department of Defense’s TRICARE program for military dependents and retirees (“Federal Settlement Agreement”). In February 2007, the Company completed separate state settlement agreements with each state Medicaid program involved in the settlement (the “State Settlement Agreements”). Under the terms of the Federal Settlement Agreement and State Settlement Agreements, the Company paid $25.1 million to the federal government and participating state Medicaid programs in connection with its billing for neonatal services provided from January 1996 through December 1999.

As part of the Federal Settlement Agreement, the Company entered into a five-year Corporate Integrity Agreement with the Office of Inspector General of the Department of Health and Human Services (the “OIG”). The Corporate Integrity Agreement acknowledges the existence of the Company’s comprehensive Compliance Plan, which provides for policies and procedures aimed at promoting the Company’s adherence with FHC Program requirements and requires the Company to maintain the Compliance Plan in full operation for the term of the Corporate Integrity Agreement. See “Government Regulation—Compliance Plan” in the Company’s most recently filed Annual Report on Form 10-K. In addition, the Corporate Integrity Agreement requires, among other things, that the Company must comply with the following integrity obligations during the term of the Corporate Integrity Agreement:

•

maintaining a Compliance Officer and Compliance Committee to administer the Company’s compliance with FHC Program requirements, the Compliance Plan and the Corporate Integrity Agreement;

•

maintaining the Code of Conduct previously developed, implemented, and distributed to the Company’s officers, directors, employees, contractors, subcontractors, agents, or other persons who provide patient care items or services (the “Covered Persons”);

•

maintaining the written policies and procedures previously developed and implemented regarding the operation of the Compliance Plan and the Company’s compliance with FHC Program requirements;

•

providing general compliance training to the Covered Persons as well as specific training to the Covered Persons who perform coding functions relating to claims for reimbursement from any FHC Program;

•

engaging an independent review organization to perform annual reviews of samples of claims from multiple hospital units to assist the Company in assessing and evaluating its coding, billing, and claims-submission practices;

•

maintaining the Disclosure Program previously developed and implemented that includes a mechanism to enable individuals to disclose, to the Chief Compliance Officer or any person who is not in the disclosing individual’s chain of command, issues or questions believed by the individual to be a potential violation of criminal, civil, or administrative laws;

•

not hiring or, if employed, removing from Pediatrix’s business operations which are related to or compensated, in whole or part, by FHC Programs, persons (i) convicted of a criminal offense related to the provision of healthcare items or services or (ii) ineligible to participate in FHC Programs or Federal procurement or nonprocurement programs;

•

notifying the OIG of (i) new investigations or legal proceedings by a governmental entity or its agents involving an allegation that Pediatrix has committed a crime or has engaged in fraudulent activities, (ii) matters that a reasonable person would consider a probable violation of criminal, civil or administrative laws applicable to any FHC Program for which penalties or exclusion may be imposed, and (iii) the purchase, sale, closure, establishment, or relocation of any facility furnishing items or services that are reimbursed under FHC Programs;

•

reporting and returning overpayments received from FHC Programs;

•

submitting reports to the OIG regarding the Company’s compliance with the Corporate Integrity Agreement; and

•

maintaining for inspection, for a period of six years from the effective date, all documents and records relating to reimbursement from the FHC Programs and compliance with the Corporate Integrity Agreement.

Failure to comply with the duties under the Corporate Integrity Agreement could result in substantial monetary penalties, and in the case of a material breach, could even result in the Company being excluded from participating in FHC Programs. Management believes the Company was in compliance with the Corporate Integrity Agreement as of June 30, 2008.

The Company expects that additional audits, inquiries and investigations from government authorities and agencies will continue to occur in the ordinary course of business. Such audits, inquiries and investigations and their ultimate resolutions, individually or in the aggregate, could have a material adverse effect on the Company’s business, financial condition, results of operations, cash flows or the trading price of the Company’s common stock.

In the ordinary course of its business, the Company becomes involved in pending and threatened legal actions and proceedings, most of which involve claims of medical malpractice related to medical services provided by its affiliated physicians. The Company’s contracts with hospitals generally require it to indemnify them and their affiliates for losses resulting from the negligence of the Company’s affiliated physicians. The Company may also become subject to other lawsuits which could involve large claims and significant defense costs. The Company believes, based upon its review of pending actions and proceedings, that the outcome of such legal actions and proceedings will not have a material adverse effect on its business, financial condition or results of operations. The outcome of such actions and proceedings, however, cannot be predicted with certainty and an unfavorable resolution of one or more of them could have a material adverse effect on its business, financial condition, results of operations and the trading price of its common stock.

Although the Company currently maintains liability insurance coverage intended to cover professional liability and certain other claims, the Company cannot assure that its insurance coverage will be adequate to cover liabilities arising out of claims asserted against it in the future where the outcomes of such claims are unfavorable. With respect to professional liability insurance, the Company self-insures its liabilities to pay deductibles through a wholly owned captive insurance subsidiary. Liabilities in excess of the Company’s insurance coverage, including coverage for professional liability and other claims, could have a material adverse effect on its business, financial condition, cash flows and results of operations.

13.

Subsequent Events:

Since June 30, 2008, the Company completed the acquisition of one anesthesiology practice and one maternal-fetal medicine practice. Total consideration paid for these acquired practices was $45.8 million in cash. The purchase agreement related to the maternal-fetal medicine practice acquisition contains contingent purchase price provisions based on certain performance measures.

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following discussion highlights the principal factors that have affected our financial condition and results of operations, as well as our liquidity and capital resources, for the periods described. This discussion should be read in conjunction with the unaudited Condensed Consolidated Financial Statements and the notes thereto included in this Quarterly Report. In addition, reference is made to our audited consolidated financial statements and notes thereto and related Management’s Discussion and Analysis of Financial Condition and Results of Operations included in our most recent Annual Report on Form 10-K. As used in this Quarterly Report, the terms “Pediatrix”, the “Company”, “we”, “us” and “our” refer to Pediatrix Medical Group, Inc. and its consolidated subsidiaries (“PMG”), together with PMG’s affiliated professional associations, corporations and partnerships (“affiliated professional contractors”). PMG has contracts with its affiliated professional contractors, which are separate legal entities that provide physician services in certain states and Puerto Rico.

The following discussion contains forward-looking statements. Please see the Company’s most recent Annual Report on Form 10-K, including the section entitled “Risk Factors,” for a discussion of the uncertainties, risks and assumptions associated with these forward-looking statements. In addition, please see “Caution Concerning Forward-Looking Statements” below.

During the six months ended June 30, 2008, we completed the acquisition of five physician group practices consisting of three cardiology practices, one maternal-fetal practice and one neonatal practice. In July 2008, we completed the acquisition of our second anesthesiology practice and a maternal-fetal practice. During the six months ended June 30, 2007, we completed the acquisition of two neonatal physician practices. Based on past results, we expect that we can improve the results of these practices through improved managed care contracting, improved collections, identification of growth initiatives, as well as operating and cost savings, based upon the significant infrastructure we have developed.

Our results of operations for the three and six months ended June 30, 2008 and 2007 include the results of operations for the physician group practices completed prior to July 2008 from their respective dates of acquisition and therefore are not comparable in some respects.

In February 2008, we completed the sale of our newborn metabolic screening laboratory business in a cash transaction for approximately $66.0 million. The sale of the laboratory is intended to allow us to focus more resources to support the continued expansion of our clinical and administrative competencies within physician services. See Note 11 to the Condensed Consolidated Financial Statements for more information regarding the sale of our newborn metabolic screening laboratory business.

During the six months ended June 30, 2008, we completed two separate $100 million share repurchase programs that were authorized by our Board of Directors in December 2007 and May 2008. In March 2008, we completed the first share repurchase program having bought approximately 1.5 million shares for approximately $100 million. In June 2008, we completed the second share repurchase program having bought approximately 1.9 million shares for approximately $100 million. All repurchases of our common stock were made in the open market subject to price, general economic and market conditions and trading restrictions.

In July 2007, the Audit Committee of our Board of Directors completed an independent comprehensive review of our stock option granting practices and made certain findings with respect to these practices. Based on these findings, management concluded that incorrect measurement dates were used for certain stock option grants in prior periods. Our results of operations for the three and six months ended June 30, 2007 include professional fees incurred in order to complete the review. In addition, our results of operations for the six months ended June 30, 2007 reflect costs to cover Internal Revenue Code Section 409A (“409A”) tax obligations on behalf of employees and other payments to employees as a result of stock option measurement date revisions.

Results of Operations

Three Months Ended June 30, 2008 as Compared to Three Months Ended June 30, 2007

Our net patient service revenue increased $34.4 million, or 15.4%, to $257.7 million for the three months ended June 30, 2008, as compared to $223.3 million for the same period in 2007. Of this $34.4 million increase, $23.2 million, or 67.4%, was attributable to revenue generated from acquisitions completed after March 31, 2007. Same-unit net patient service revenue increased $11.2 million, or 5.1%, for the three months ended June 30, 2008. The change in same-unit net patient service revenue was the result of increased revenue of approximately $9.7 million related to pricing and reimbursement factors and approximately $1.5 million from higher patient service volumes. The net increase in revenue of $9.7 million related to pricing and reimbursement factors is primarily due to: (i) improved managed care contracting; (ii) increased reimbursement for physician services from the Texas Medicaid program beginning in September 2007; and (iii) increased revenue related to hospital contract administrative fees due to expanded services in existing practices. Our net increase in revenue of $1.5 million from higher patient service volumes includes $3.9 million from volume growth in maternal-fetal, pediatric cardiology and other services, including hearing screens and newborn nursery services, partially offset by decreased revenue of $2.4 million from a 1.4% decrease in neonatal intensive care unit patient days. Same units are those units at which we provided services for the entire current period and the entire comparable period.

Practice salaries and benefits increased $24.6 million, or 19.5%, to $150.7 million for the three months ended June 30, 2008, as compared to $126.1 million for the same period in 2007. This $24.6 million increase was attributable to: (i) increased costs associated with new physicians and other staff of approximately $22.6 million to support acquisition-related growth and volume growth at existing units; and (ii) an increase in incentive compensation of $2.0 million as a result of operational improvements at the physician-practice level and an increase in the number of physician practices participating in our incentive compensation program.

Practice supplies and other operating expenses increased $2.0 million, or 23.9%, to $10.5 million for the three months ended June 30, 2008, as compared to $8.5 million for the same period in 2007. The increase was primarily attributable to supply and maintenance costs and other costs to support acquisition-related growth.

General and administrative expenses include all billing and collection functions and all other salaries, benefits, supplies and operating expenses not specifically related to the day-to-day operations of our physician group practices. General and administrative expenses increased $1.7 million, or 5.9%, to $31.0 million for the three months ended June 30, 2008, as compared to $29.3 million for the same period in 2007. This $1.7 million net increase was primarily due to an increase in salaries and benefits and other general and administrative expenses of $3.5 million related to the continued growth of the Company partially offset by a decrease in costs, on a comparative basis, related to stock option review professional fees of $1.8 million incurred during the three months ended June 30, 2007.

Depreciation and amortization expense increased by $720,000, or 32.4%, to $2.9 million for the three months ended June 30, 2008, as compared to $2.2 million for the same period in 2007. This increase was attributable to the depreciation of fixed asset additions and the amortization of intangible assets related to acquisitions.

Income from operations increased $5.3 million, or 9.3%, to $62.5 million for the three months ended June 30, 2008, as compared to $57.2 million for the same period in 2007. Our operating margin decreased to 24.3% for the three months ended June 30, 2008, as compared to 25.6% for the same period in 2007. This net decrease of 1.3% is primarily due to: (i) the addition of anesthesia services and growth in our office-based practices which have lower operating margins than neonatal services; and (ii) lower volume in our neonatal practices; partially offset by (iii) improved management of general and administrative expenses during the three months ended June 30, 2008; and (iv) a decrease in costs, on a comparative basis, related to stock option review professional fees of $1.8 million incurred during the three months ended June 30, 2007.

We recorded net investment income of $310,000 for the three months ended June 30, 2008, as compared to net investment income of $1.5 million for the same period in 2007. The decrease in net investment income is primarily due to a decrease in funds available to invest as a result of stock repurchase programs and practice acquisitions completed during 2008, as well as lower returns on our outstanding investment balances. Interest expense for the three months ended June 30, 2008 and 2007, consisted of interest charges, commitment fees and amortized debt costs associated with our revolving credit facility (“Line of Credit”).

Our effective income tax rate was 39.25% for the three months ended June 30, 2008, as compared to 39.20% for the same period in 2007.

Income from continuing operations increased $2.5 million, or 6.9%, to $38.2 million for the three months ended June 30, 2008, as compared to $35.7 million for the same period in 2007. Income from continuing operations for the three months ended June 30, 2007 includes after-tax costs of $1.1 million for professional fees related to our stock option review.

Diluted income from continuing operations per common and common equivalent share was $.80 on weighted average shares outstanding of 47.7 million for the three months ended June 30, 2008, as compared to $.71 on weighted average shares outstanding of 50.1 million for the same period in 2007. The net decrease in weighted average shares outstanding was primarily due to the impact of shares repurchased in late 2007 and 2008 under repurchase programs approved by our Board of Directors in August 2007, December 2007 and May 2008, partially offset by an increase in weighted average shares from the exercise of employee stock options, the vesting of restricted stock and the issuance of shares under our Stock Purchase Plans.

Loss from discontinued operations, net of income taxes for the three months ended June 30, 2008 was $1.2 million, compared to income from discontinued operations, net of income taxes of $612,000 for the three months ended June 30, 2007. In February 2008, we completed the sale of our newborn metabolic screening laboratory business in a cash transaction for approximately $66.0 million. The loss from discontinued operations, net of income taxes of $1.2 million for the three months ended June 30, 2008 is related to the correction of certain deferred taxes related to the sale of our newborn metabolic screening laboratory business. Income from discontinued operations, net of income taxes of $612,000 for the three months ended June 30, 2007 represents the financial results of our newborn metabolic screening laboratory business. See Note 11 to the Condensed Consolidated Financial Statements for more information regarding the sale of our newborn metabolic screening laboratory business.

Net income increased to $37.0 million for the three months ended June 30, 2008, as compared to $36.3 million for the same period in 2007.

Diluted net income per common and common equivalent share was $.78 on weighted average shares outstanding of 47.7 million for the three months ended June 30, 2008, as compared to $.72 on weighted average shares outstanding of 50.1 million for the same period in 2007.

Six Months Ended June 30, 2008 as Compared to Six Months Ended June 30, 2007

Our net patient service revenue increased $69.1 million, or 15.9%, to $503.3 million for the six months ended June 30, 2008, as compared to $434.2 million for the same period in 2007. Of this $69.1 million increase, $41.6 million, or 60.2%, was attributable to revenue generated from acquisitions completed after December 31, 2006. Same-unit net patient service revenue increased $27.5 million, or 6.5%, for the six months ended June 30, 2008. The change in same-unit net patient service revenue was the result of increased revenue of approximately $19.3 million related to pricing and reimbursement factors and approximately $8.2 million from higher patient service volumes. The net increase in revenue of $19.3 million related to pricing and reimbursement factors is primarily due to: (i) improved managed care contracting; (ii) increased reimbursement for physician services from the Texas Medicaid program beginning in September 2007; and (iii) increased revenue related to hospital contract administrative fees due to expanded services in existing practices. Increased revenue of $8.2 million from higher patient service volumes includes $7.6 million from volume growth in maternal-fetal, pediatric cardiology and other services, including hearing screens and newborn nursery services and $646,000 from a .2% increase in neonatal intensive care unit patient days. Excluding the additional calendar day in February for the 2008 leap year, neonatal intensive care unit patient days decreased by .3%. Same units are those units at which we provided services for the entire current period and the entire comparable period.

Practice salaries and benefits increased $45.7 million, or 17.8%, to $302.1 million for the six months ended June 30, 2008, as compared to $256.4 million for the same period in 2007. The net increase was primarily attributable to: (i) increased costs associated with new physicians and other staff of approximately $43.0 million to support acquisition-related growth and volume growth at existing units; and (ii) an increase in incentive compensation of $5.7 million as a result of operational improvements at the physician-practice level and an increase in the number of physician practices participating in our incentive compensation program; partially offset by (iii) a decrease in costs, on a comparative basis, related to 409A tax obligations of $3.0 million accrued during the six months ended June 30, 2007.

Practice supplies and other operating expenses increased $3.8 million, or 23.8%, to $20.2 million for the six months ended June 30, 2008, as compared to $16.4 million for the same period in 2007. The increase was primarily attributable to supply and maintenance costs and other costs to support acquisition-related growth and volume growth at existing units.

General and administrative expenses include all billing and collection functions and all other salaries, benefits, supplies and operating expenses not specifically related to the day-to-day operations of our physician group practices. General and administrative expenses decreased $1.5 million, or 2.5%, to $60.8 million for the six months ended June 30, 2008, as compared to $62.3 million for the same period in 2007. This $1.5 million net decrease was primarily due to: (i) a decrease in costs, on a comparative basis, related to 409A tax obligations of $3.4 million accrued during the six months ended June 30, 2007; and (ii) a decrease in costs, on a comparative basis, related to stock option review professional fees of $3.3 million incurred during the six months ended June 30, 2007; partially offset by (iii) an increase in salaries and benefits and other general and administrative expenses of $5.2 million related to the continued growth of the Company.

Depreciation and amortization expense increased by $1.4 million, or 30.9%, to $5.8 million for the six months ended June 30, 2008, as compared to $4.4 million for the same period in 2007. This increase was attributable to the depreciation of fixed asset additions and the amortization of intangible assets related to acquisitions.

Income from operations increased $19.8 million, or 20.9%, to $114.5 million for the six months ended June 30, 2008, as compared to $94.7 million for the same period in 2007. Our operating margin increased to 22.7% for the six months ended June 30, 2008, as compared to 21.8% for the same period in 2007. The net increase in our operating margin is primarily due to: (i) decreased costs, on a comparative basis, of $9.7 million related to 409A tax obligations and stock option review professional fees incurred during the six months ended June 30, 2007; and (ii) improved management of general and administrative expenses during the six months ended June 30, 2008; partially offset by (iii) a decline in operating margin related to the addition of anesthesia services and growth in our office-based practices which have a lower operating margin than neonatal services, and lower volume in our neonatal practices.

We recorded net investment income of $1.2 million for the six months ended June 30, 2008, as compared to net investment income of $3.2 million for the same period in 2007. The decrease in net investment income is primarily due to a decrease in funds available to invest as a result of stock repurchase programs and practice acquisitions completed in late 2007 and the first half of 2008, as well as lower returns on our outstanding investment balances. Interest expense for the six months ended June 30, 2008 and 2007, consisted of interest charges, commitment fees and amortized debt costs associated with our revolving Line of Credit.

Our effective income tax rate was 39.23% for the six months ended June 30, 2008, as compared to 37.98% for the same period in 2007. Our effective tax rate for the six months ended June 30, 2007 was affected by the recognition of $1.2 million of tax benefits on uncertain tax positions as a result of the expiration of the statute of limitations on certain filed tax returns. The tax benefit related to 2007 was partially offset by an increase in our provision for uncertain tax positions as a result of the adoption of FASB Interpretation No. 48, “Accounting for Uncertainty in Income Taxes – an interpretation of FASB Statement No. 109” (“FIN 48”) and increased taxes as a result of tax law changes in the State of Texas. We anticipate our effective tax rate will be approximately 39.25% for all of 2008, excluding any adjustments related to reductions in liabilities for uncertain tax positions.

Income from continuing operations increased $9.6 million, or 15.8%, to $70.3 million for the six months ended June 30, 2008, as compared to $60.7 million for the same period in 2007. Income from continuing operations for the six months ended June 30, 2007 includes $6.0 million for the after-tax impact of costs to cover 409A tax obligations and professional fees related to our stock option review, and the recognition of $1.2 million of tax benefits on uncertain tax positions.

Diluted income from continuing operations per common and common equivalent share was $1.46 on weighted average shares outstanding of 48.3 million for the six months ended June 30, 2008, as compared to $1.21 on weighted average shares outstanding of 50.0 million for the same period in 2007. The net decrease in weighted average shares outstanding was primarily due to the impact of shares repurchased in late 2007 and through June 2008 under repurchase programs approved by our Board of Directors in August 2007, December 2007 and May 2008 partially offset by an increase in weighted average shares from the exercise of employee stock options, the vesting of restricted stock and the issuance of shares under our Stock Purchase Plans.

Income from discontinued operations, net of income taxes for the six months ended June 30, 2008 was $22.5 million, compared to $1.2 million for the same period in 2007. Income from discontinued operations represents the financial results of our newborn metabolic screening laboratory business. In February 2008, we completed the sale of our newborn metabolic screening laboratory business in a cash transaction for approximately $66.0 million. The increase in income from discontinued operations for the six months ended June 30, 2008 is due to the gain on the sale of this business, net of income taxes, of $22.0 million. See Note 11 to the Condensed Consolidated Financial Statements for more information regarding the sale of our newborn metabolic screening laboratory business.

Net income increased to $92.8 million for the six months ended June 30, 2008, as compared to $61.9 million for the same period in 2007. Net income for the six months ended June 30, 2008 includes the after-tax gain of $22.0 million on the sale of our newborn metabolic screening business.

Diluted net income per common and common equivalent share was $1.92 on weighted average shares outstanding of 48.3 million for the six months ended June 30, 2008, as compared to $1.24 on weighted average shares outstanding of 50.0 million for the same period in 2007.

Liquidity and Capital Resources

As of June 30, 2008, we had $14.2 million of cash and cash equivalents on hand as compared to $102.8 million at December 31, 2007. In addition, we had working capital of $24.6 million at June 30, 2008, a decrease of $74.6 million from working capital of $99.2 million at December 31, 2007. This net decrease in working capital is primarily due to the use of funds for the repurchase of common stock under our most recent share repurchase programs and physician practice acquisition payments, partially offset by year-to-date earnings from continuing operations, borrowings under our Line of Credit, the after-tax gain of $22.0 million on the sale of our newborn metabolic screening laboratory business and proceeds from the exercise of employee stock options and the issuance of common stock under our Stock Purchase Plans.

Our net cash provided from operating activities was $30.0 million for the six months ended June 30, 2008, as compared to net cash provided from operating activities of $36.3 million for the same period in 2007. The net decrease in our cash provided from operating activities for the six months ended June 30, 2008 is primarily due to: (i) an increase in cash used in operations from an increase in our annual payments due under our performance-based incentive compensation program; and (ii) higher tax payments, on a comparative basis, for the six months ended June 30, 2008 partially offset by (iii) improved operating results; and (iv) improved collections on accounts receivable. Our operating results for the six months ended June 30, 2007 were affected by increased costs of $9.7 million related to 409A tax obligations and professional fees related to our stock option review.

During the six months ended June 30, 2008, accounts receivable increased by $3.1 million, as compared to an increase of $7.3 million for the same period in 2007. The net increase in accounts receivable during the six months ended June 30, 2008 is due to an increase in net patient service revenue related to physician group practice acquisitions partially offset by improved cash collections.

Our accounts receivable are principally due from managed care payors, government payors, and other third-party insurance payors. We track our collections from these sources, monitor the age of our accounts receivable, and make all reasonable efforts to collect outstanding accounts receivable through our systems, processes and personnel at our corporate and regional billing and collection offices. We use customary collection practices, including the use of outside collection agencies, for accounts receivable due from private pay patients when appropriate. Almost all of our accounts receivable adjustments consist of contractual adjustments due to the difference between gross amounts billed and the amounts allowed by our payors. Any amounts written off related to private pay patients are based on the specific facts and circumstances related to each individual patient account.

Days sales outstanding (“DSO”) is one of the key factors that we use to evaluate the condition of our accounts receivable and the related allowances for contractual adjustments and uncollectibles. DSO reflects the timeliness of cash collections on billed revenue and the level of reserves on outstanding accounts receivable. Since December 31, 2007, our DSO has decreased slightly from 53.5 days at December 31, 2007 to 52.5 days at June 30, 2008.

During the six months ended June 30, 2008, cash used in operating activities related to accounts payable and accrued expenses was $40.9 million, compared to $27.3 million for the same period in 2007. This $13.6 million net increase is primarily due to an increase in our annual payments due under our performance-based incentive compensation program.

During the six months ended June 30, 2008, net cash used in operating activities included tax payments of approximately $51.5 million, as compared to tax payments of approximately $45.5 million for the same period in 2007.

During the six months ended June 30, 2008, our net cash provided from investing activities of $11.8 million included the proceeds from the sale of our newborn metabolic screening laboratory business of $66.0 million and net proceeds of $1.6 million related to the purchase and maturity of investments, partially offset by physician group practice acquisition payments of $47.7 million and capital expenditures of $8.2 million. Our physician group practice acquisitions consisted of three cardiology practices, one maternal-fetal practice and one neonatal practice. Our capital expenditures were for medical equipment, computer and office equipment, software, furniture and other improvements at our office-based practices and our corporate and regional offices.

During the six months ended June 30, 2008, our net cash used in financing activities of $130.3 million consisted primarily of the repurchase of $200 million of our common stock under the share repurchase programs approved by our Board of Directors in December 2007 and May 2008, partially offset by net borrowings under our Line of Credit of $57.5 million, proceeds from the exercise of employee stock options and the issuance of common stock under our Stock Purchase Plans of $8.6 million, and $4.0 million from the excess tax benefit of stock option exercises and restricted stock vestings.

Our $225 million Line of Credit includes a $25 million subfacility for the issuance of letters of credit. At our option, the Line of Credit bears interest at (i) the base rate (defined as the higher of the Federal Funds Rate plus .5% or the Bank of America prime rate) or (ii) the Eurodollar rate plus an applicable margin rate ranging from .75% to 1.75% based on our consolidated leverage ratio. Our Line of Credit is collateralized by substantially all of our assets. We are subject to certain covenants and restrictions specified in the Line of Credit, including covenants that require us to maintain a minimum level of net worth and that restrict us from paying dividends and making certain other distributions as specified therein. Failure to comply with these covenants and restrictions would constitute an event of default under the Line of Credit, notwithstanding our ability to meet our debt service obligations. Our Line of Credit includes various customary remedies for our lenders following an event of default. Our Line of Credit matures in July 2009 and we are currently in the process of obtaining a new line of credit.

At June 30, 2008, we believe we were in compliance with the financial covenants and other restrictions applicable to us under the Line of Credit. At June 30, 2008, we had an outstanding principal balance of $57.5 million on our Line of Credit. We also had outstanding letters of credit of $12.2 million which reduced the amount available on our Line of Credit at June 30, 2008.

We maintain professional liability insurance policies with third-party insurers, subject to self-insured retention, exclusions and other restrictions. We self-insure our liabilities to pay self-insured retention amounts under our professional liability insurance coverage through a wholly owned captive insurance subsidiary. We record a liability for self-insured amounts and an estimate of liabilities for claims incurred but not reported based on an actuarial valuation using historical loss patterns.

We anticipate that funds generated from operations, together with our current cash on hand, short-term investments and funds available under the Line of Credit, will be sufficient to finance our working capital requirements, fund anticipated acquisitions and capital expenditures, and meet our contractual obligations for at least the next 12 months.

Our cash equivalents typically consist of money market funds, commercial paper and overnight repurchase agreements. Our investments consist entirely of held-to-maturity securities issued primarily by the U.S. Treasury, other U.S. Government corporations and agencies and states of the United States. Our investment policy is intended to preserve principal and minimize credit risk. All investment purchases are subject to maturity limit restrictions and high credit rating standards.

Contractual Obligations

Effective January 1, 2007, we adopted the provisions of FASB Interpretation No. 48, “Accounting for Uncertainty in Income Taxes – an interpretation of FASB Statement No. 109” (“FIN 48”). FIN 48 prescribes a recognition threshold and measurement attribute for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. Accounting for uncertain tax positions under FIN 48 requires significant judgment and analyses as well as assumptions about future events. At June 30, 2008, our total liability for unrecognized tax benefits was $22.0 million, and the current portion of this liability was $10.5 million. Although we believe our liability for unrecognized tax benefits is adequate, it is difficult to predict the final outcome or the timing of the resolution of any particular tax matter. We may need to adjust our liability for unrecognized tax benefits as relevant circumstances evolve and we cannot predict when, or if, any future tax payments related to our uncertain tax positions may occur.

Caution Concerning Forward-Looking Statements

Certain information included or incorporated by reference in this Quarterly Report may be deemed to be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may include, but are not limited to, statements relating to our objectives, plans and strategies, and all statements (other than statements of historical facts) that address activities, events or developments that we intend, expect, project, believe or anticipate will or may occur in the future are forward-looking statements. These statements are often characterized by terminology such as “believe,” “hope,” “may,” “anticipate,” “should,” “intend,” “plan,” “will,” “expect,” “estimate,” “project,” “positioned,” “strategy” and similar expressions and are based on assumptions and assessments made by our management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. Any forward-looking statements in this Quarterly Report are made as of the date hereof, and we undertake no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Important factors that could cause actual results, developments and business decisions to differ materially from forward-looking statements are described in the Company’s most recent Annual Report on Form 10-K, including the section entitled “Risk Factors.”

Item 3.

Quantitative and Qualitative Disclosures about Market Risk

Our Line of Credit is subject to market risk and interest rate changes and bears interest at our option at (i) the base rate (defined as the higher of the Federal Funds Rate plus .5% or the Bank of America prime rate) or (ii) the Eurodollar rate plus an applicable margin rate ranging from .75% to 1.75% based on our consolidated leverage ratio. There was $57.5 million of outstanding principal under our Line of Credit at June 30, 2008. However, for every $10 million outstanding on our Line of Credit, a 1% change in interest rates would result in an impact to income before taxes of $100,000 per year.

Item 4.

Controls and Procedures

Evaluation of Disclosure Controls and Procedures

The Company maintains disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended) that are designed to provide reasonable assurance that information required to be disclosed by the Company in reports it files or submits under the Exchange Act is (i) recorded, processed, summarized and reported within the time periods specified in SEC rules and forms and (ii) accumulated and communicated to the Company’s management, including its principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.

We carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of our disclosure controls and procedures. Based upon that evaluation, the Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures were effective as of the end of the period covered by this report.

Changes in Internal Controls Over Financial Reporting

No changes in our internal control over financial reporting occurred during the quarter ended June 30, 2008 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II - OTHER INFORMATION

Item 1.

Legal Proceedings

In July 2007, the Audit Committee of our Board of Directors concluded a comprehensive review of our historical practices related to the granting of stock options with the assistance of independent legal counsel and forensic accounting experts. At the commencement of the review, we voluntarily contacted the staff of the Securities and Exchange Commission (“SEC”) regarding the Audit Committee’s review and subsequently the SEC notified us that it had commenced a formal investigation into our stock option granting practices. We also had discussions with the U.S. Attorney’s office for the Southern District of Florida regarding the Audit Committee’s review and, in response to a subpoena, provided the office with various documents and information related to our stock option granting practices. We intend to continue full cooperation with the U.S. Attorney’s office and the SEC. We cannot predict the outcome of these matters.

In April 2008, the United States District Court for the Southern District of Florida entered a final judgment approving a Stipulation of Settlement to resolve a shareholder derivative lawsuit that was filed by Jacob Schwartz in the United States District Court for the Southern District of Florida in August 2007, naming us as a nominal defendant and also naming as defendants certain current and former officers and directors. The lawsuit alleged that all or some of the defendant officers and directors, among other things, breached their fiduciary duties to the Company, violated the federal securities laws, and engaged in corporate waste, gross mismanagement, unjust enrichment and constructive fraud in connection with our historical stock option practices. In consideration for the full settlement and release of claims against all defendants, the Stipulation of Settlement provided for our payment of $1.5 million in attorneys’ fees and costs to the plaintiff’s counsel and recognition that the plaintiff’s demand letter, which was received prior to the commencement of the lawsuit, was a significant contributing factor to the implementation of various measures to enhance our stock option practices. The payment to the plaintiff’s counsel was covered by insurance.

In September 2006, we completed a final settlement agreement with the Department of Justice and a relator who initiated a “qui tam” complaint against us relating to our billing practices for services reimbursed by Medicaid, the Federal Employees Health Benefit program, and the United States Department of Defense’s TRICARE program for military dependents and retirees (“Federal Settlement Agreement”). In February 2007, we completed separate state settlement agreements with each state Medicaid program involved in the settlement (the “State Settlement Agreements”). Under the terms of the Federal Settlement Agreement and State Settlement Agreements, we paid $25.1 million to the federal government and participating state Medicaid programs in connection with our billing for neonatal services provided from January 1996 through December 1999.

As part of the Federal Settlement Agreement, we entered into a five-year Corporate Integrity Agreement with the Office of Inspector General of the Department of Health and Human Services (the “OIG”). The Corporate Integrity Agreement acknowledges the existence of our comprehensive Compliance Plan, which provides for policies and procedures aimed at promoting our adherence with FHC Program requirements and requires us to maintain the Compliance Plan in full operation for the term of the Corporate Integrity Agreement. See “Government Regulation—Compliance Plan” in our most recently filed Annual Report on Form 10-K. In addition, the Corporate Integrity Agreement requires, among other things, that we must comply with the following integrity obligations during the term of the Corporate Integrity Agreement:

•

maintaining a Compliance Officer and Compliance Committee to administer our compliance with FHC Program requirements, the Compliance Plan and the Corporate Integrity Agreement;

•

maintaining the Code of Conduct previously developed, implemented, and distributed to our officers, directors, employees, contractors, subcontractors, agents, or other persons who provide patient care items or services (the “Covered Persons”);

•

maintaining the written policies and procedures previously developed and implemented regarding the operation of the Compliance Plan and our compliance with FHC Program requirements;

•

engaging an independent review organization to perform annual reviews of samples of claims from multiple hospital units to assist us in assessing and evaluating our coding, billing, and claims-submission practices;

•

not hiring or, if employed, removing from our business operations which are related to or compensated, in whole or part, by FHC Programs, persons (i) convicted of a criminal offense related to the provision of healthcare items or services or (ii) ineligible to participate in FHC Programs or Federal procurement or nonprocurement programs;

•

notifying the OIG of (i) new investigations or legal proceedings by a governmental entity or its agents involving an allegation that we have committed a crime or have engaged in fraudulent activities, (ii) matters that a reasonable person would consider a probable violation of criminal, civil or administrative laws applicable to any FHC Program for which penalties or exclusion may be imposed, and (iii) the purchase, sale, closure, establishment, or relocation of any facility furnishing items or services that are reimbursed under FHC Programs;

•

reporting and returning overpayments received from FHC Programs;

•

submitting reports to the OIG regarding our compliance with the Corporate Integrity Agreement; and

•

Failure to comply with the duties under the Corporate Integrity Agreement could result in substantial monetary penalties and in the case of a material breach, could even result in us being excluded from participating in FHC Programs. We believe we were in compliance with the Corporate Integrity Agreement as of June 30, 2008.

We expect that additional audits, inquiries and investigations from government authorities and agencies will continue to occur in the ordinary course of business. Such audits, inquiries and investigations and their ultimate resolutions, individually or in the aggregate, could have a material adverse effect on our business, financial condition, results of operations, cash flows or the trading price of our common stock.

In the ordinary course of our business, we become involved in pending and threatened legal actions and proceedings, most of which involve claims of medical malpractice related to medical services provided by our affiliated physicians. Our contracts with hospitals generally require us to indemnify them and their affiliates for losses resulting from the negligence of our affiliated physicians. We may also become subject to other lawsuits which could involve large claims and significant defense costs. We believe based upon our review of pending actions and proceedings, that the outcome of such legal actions and proceedings will not have a material adverse effect on our business, financial condition or results of operations. The outcome of such actions and proceedings, however, cannot be predicted with certainty and an unfavorable resolution of one or more of them could have a material adverse effect on our business, financial condition, results of operations and the trading price of our common stock.

Although we currently maintain liability insurance coverage intended to cover professional liability and certain other claims, we cannot assure that our insurance coverage will be adequate to cover liabilities arising out of claims asserted against us in the future where the outcomes of such claims are unfavorable. With respect to professional liability insurance, we self-insure our liabilities to pay deductibles through a wholly owned captive insurance subsidiary. Liabilities in excess of our insurance coverage, including coverage for professional liability and other claims, could have a material adverse effect on our business, financial condition, cash flows and results of operations.

Item 1A.

Risk Factors

There have been no material changes to the risk factors previously disclosed in the Company’s most recent Annual Report on Form 10-K.

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

During the three months ended June 30, 2008, we completed the repurchase of approximately 1.9 million shares of our common stock in connection with a $100 million repurchase program that was approved by our Board of Directors in May 2008. All repurchases were made in open market transactions, subject to market conditions and trading restrictions.


Period	Total Number of Shares Purchased	Average Price Paid Per Share		Total Number of Shares Purchased as Part of the Repurchase Program	Approximate Dollar Value of Shares that May Yet Be Purchased Under the Repurchase Program (in thousands)
April 1, 2008 to April 30, 2008	—		—	—		—

May 1, 2008 to May 31, 2008	—		—	—	$	100,000

June 1, 2008 to June 30, 2008	1,859,900	$	53.76	1,859,900		—

Total	1,859,900			1,859,900

Item 4.

Submission of Matters to a Vote of Security-Holders

At the Company’s Annual Meeting of Shareholders on May 23, 2008, the shareholders of record as of March 25, 2008 voted on the following matters:

Proposal 1: Election of Directors:


Name	For	Withheld	Abstained	Broker Non-Vote
Cesar L. Alvarez	39,508,312	5,205,914	0	0

Waldemar A. Carlo, M.D.	43,727,858	986,368	0	0

Michael B. Fernandez	41,834,789	2,879,437	0	0

Roger K. Freeman, M.D.	39,286,556	5,427,670	0	0

Paul G. Gabos	43,887,402	826,824	0	0

Pascal J. Goldschmidt, M.D.	40,195,343	4,518,883	0	0

Roger J. Medel, M.D.	43,545,581	1,168,645	0	0

Manuel Kadre	44,111,552	602,674	0	0

Enrique J. Sosa, Ph.D	43,887,918	826,308	0	0

Proposal 2: Approval of the Company’s 2008 Incentive Compensation Plan:

For

Withheld

Abstained

Broker

Non-Vote

35,984,406

6,083,190

9,779

2,636,851

Proposal 3: Ratification of the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the 2008 fiscal year:

For

Withheld

Abstained

Broker

Non-Vote

43,683,683

1,024,677

5,865

Item 6.

Exhibits

See Exhibit Index.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


	PEDIATRIX MEDICAL GROUP, INC.

Date: August 5, 2008	By:	/s/ Roger J. Medel, M.D.
		Roger J. Medel, M.D., Chief Executive Officer (principal executive officer)

Date: August 5, 2008	By:	/s/ Karl B. Wagner
		Karl B. Wagner, Chief Financial Officer (principal financial officer)

EXHIBIT INDEX


Exhibit No.		Description
3.1		Composite Articles of Incorporation of Pediatrix (incorporated by reference to Exhibit 3.1 to Pediatrix’s Quarterly Report on Form 10-Q for the period ended March 31, 2006).

3.2		Amended and Restated Bylaws of Pediatrix (incorporated by reference to Exhibit 3.2 to Pediatrix’s Current Report on Form 8-K dated April 7, 2008).

3.3		Articles of Designation of Series A Junior Participating Preferred Stock of Pediatrix (incorporated by reference to Exhibit 3.1 to Pediatrix’s Current Report on Form 8-K dated March 31, 1999).

4.1		Rights Agreement, dated as of March 31, 1999, between Pediatrix and BankBoston, N.A., as rights agent including the form of Articles of Designations of Series A Junior Participating Preferred Stock and the form of Rights Certificate (incorporated by reference to Exhibit 4.1 to Pediatrix’s Current Report on Form 8-K dated March 31, 1999).

4.2		Amendment No. 1, dated March 28, 2008, to Rights Agreement, dated as of March 31, 1999, between Pediatrix and Computershare Trust Company, N.A. (successor rights agent to BankBoston, N.A.), (incorporated by reference to Exhibit 4.1 to Pediatrix’s Current Report on Form 8-K dated March 28, 2008).

4.3		Certificate of Adjustment to the Rights Agreement between Pediatrix and Computershare Trust Company N.A. (as successor to BankBoston, N.A.) as rights agent (incorporated by reference to Exhibit 4.2 to Pediatrix’s Current Report on Form 8-K dated April 27, 2006).

31.1+		Certification of Chief Executive Officer pursuant to Securities Exchange Act Rule 13a-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2+		Certification of Chief Financial Officer pursuant to Securities Exchange Act Rule 13a-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32+		Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

+	Filed herewith.

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents